Has Todd Borus, MD received payments from drug or device companies?

Yes. Drug and device makers reported $357,167 in general payments to Todd Borus, MD across 254 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Todd Borus, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Todd Borus, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Todd Borus, MD

Orthopaedic Surgery · Vancouver, WANPI 1700858651

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $250,750 of the $357,167 with a category attached, or 70.2%. Stryker accounts for 82.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $133,836 and has fallen 77.4% since, to $30,250 in 2025. Among orthopaedic surgery clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$357,167in general payments, 2019–2025

Across 254 payments — averaging $1406.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Stryker$294K
Globus Medical$31K
Nextstep Arthropedix, LLC$31K
Johnson & Johnson$446
Davol Inc.$298
Vertex$125
plus $203 from 3 others

$35,432in research payments, 2019–2025

Across 13 payments — averaging $2725.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Stryker$35K

$105,984in ownership & investment interests, 2019–2025

Across 5 payments — averaging $21,197 each. An ownership or investment interest held by the physician or an immediate family member.

Lazurite Inc.$106K

What the payments were for

Royalty or licence$29,2528%
Consulting fees$250,75070%
Speaking & faculty fees$7,2002%
Travel & lodging$61,88017%
Food & beverage$8,0852%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Stryker	213	$294,159
Globus Medical	25	$31,433
Nextstep Arthropedix, LLC	4	$30,503
Johnson & Johnson	4	$446
Davol Inc.	3	$298
Vertex	1	$125
Pacira Pharmaceuticals Incorporated	1	$117
Avanos Medical	2	$50
Zimmer Biomet	1	$36

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

MAKO$288,161
iNSitu Hip System$30,434
Verasense$19,000
ExcelsiusGPS Robotic Navigation System$14,084
Onvoy$12,600
MOTIONSENSE DIGITAL GONIOMETER$9,500
Legacy Stelkast Knee$3,406
TRIATHLON$2,838
Excelsius - GPS$891
ATTUNE$358
ACCOLADE$318
Provident II Hip System$284
Genflex2 Total Knee System$284
AEQUALIS$198
ARISTA AH FLEXITIP$132
JOURNAVX$125
Iovera$117

How this compares

$357,167 in reported general payments places this provider in the 95th percentile of 495 orthopaedic surgery providers in Washington.

See all orthopaedic surgery providers in Washington →

Medicare billing

Part B allowed, 2024

$287,475

Medicare patients

374

Services billed

3,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Celecoxib	125	$2,202
Mupirocin	88	$621
Cephalexin	263	$539
Ondansetron OdtOndansetron	78	$399
Oxycodone Hcl	49	$251
Dexamethasone	52	$176
Hydromorphone Hcl	33	$174
Clindamycin Hcl	34	$53

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Vancouver

William BarrettRenton$7.7M
James PritchettSeattle$6.4M
James CrutcherSeattle$3.5M
Keith MayoSeattle$3.1M
Matthew SaltzmanSeattle$1.8M
Tim LovellSpokane$1.8M
Timothy AltonRenton$1.5M
Burt YaszaySeattle$1.3M
Sean ToomeySeattle$1.2M
Richard WilliamsonMount Vernon$1.1M

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →